In summary, defining the new organizational structure involves setting clear strategic objectives for the drug development paths, forming cross-functional teams to enhance collaboration and adaptability, and adjusting reporting lines to ensure efficient decision-making and communication. This structural transformation allows the company to better align with its strategic goals and respond more effectively to the dynamic biotechnology industry